Compounds > db293
Page last updated: 2024-12-08

db293

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

DB293: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID459929
CHEMBL ID62071
SCHEMBL ID12348382
MeSH IDM0458337

Synonyms (15)

Synonym
2-[5-(4-carbamimidoylphenyl)-2-furyl]-1h-benzimidazole-5-carboxamidine
216308-19-9
2-(5-amidino-2-benzimidazolyl)-5-(4-amidinophenyl)furan
2-[5-(4-carbamimidoylphenyl)-2-furyl]-3h-benzimidazole-5-carboxamidine
1h-benzimidazole-5-carboximidamide, 2-[5-[4-(aminoiminomethyl)phenyl]-2-furanyl]-
2-(5-{4-[amino(imino)methyl]phenyl}-2-furyl)-1h-benzimidazole-5-carboximidamide
2-[5-(4-carbamimidoylphenyl)furan-2-yl]-3h-benzimidazole-5-carboximidamide
CHEMBL62071
1h-benzimidazole-5-carboximidamide, 2-(5-(4-(aminoiminomethyl)phenyl)-2-furanyl)-
SCHEMBL12348382
DTXSID90176021
db 293
2-[5-(4-carbamimidoylphenyl)furan-2-yl]-1h-benzimidazole-5-carboximidamide
Q27463056
db293

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"1% of control when administered at a dosage of 10 micromol/kg."( Extended aromatic furan amidino derivatives as anti-Pneumocystis carinii agents.
Bajic, M; Bender, BC; Boykin, DW; Hall, JE; Hopkins, KT; Kumar, A; McCurdy, DR; Tidwell, RR; Wilson, WD, 1998)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1755260Inhibition of HOXA9 (unknown origin) expressed in reticulocyte lysate system binding to DNA Hoxa9-binding site (5'-biotin-cctctcctctcctGCGATGATTTACGACCGC) (unknown origin) assessed as Hoxa9/DNA remaining complexes at 5 to 10 uM incubated for 20 mins with 2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Heterocyclic Diamidine DNA Ligands as HOXA9 Transcription Factor Inhibitors: Design, Molecular Evaluation, and Cellular Consequences in a HOXA9-Dependant Leukemia Cell Model.
AID1755259Drug localization in nucleus of human HT-29 cells at 5 uM incubated for 16 hrs by DiOC6/propidium iodide staining based by fluorescence microscopy2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Heterocyclic Diamidine DNA Ligands as HOXA9 Transcription Factor Inhibitors: Design, Molecular Evaluation, and Cellular Consequences in a HOXA9-Dependant Leukemia Cell Model.
AID192581In vivo evaluation of iv dosage of the Dicationic furans against Pneumocystis carinii in lung tissue of rats at 5 umol/kg/day1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Extended aromatic furan amidino derivatives as anti-Pneumocystis carinii agents.
AID212857In vivo evaluation of iv dosage of the Dicationic furans against Pneumocystis carinii in rats measured 5 umol/kg/day1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Extended aromatic furan amidino derivatives as anti-Pneumocystis carinii agents.
AID1755264Inhibition of HOXA9 (unknown origin) expressed in reticulocyte lysate system binding to 32P-radiolabeled DNA Hoxa9-binding site (strand a-CTGCGATGATTTACGACCGC /strand b-GCGGTCGTAAATCATCGCAG) (unknown origin) assessed as HOXA9/DNA inhibition at 2.5 to 20 u2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Heterocyclic Diamidine DNA Ligands as HOXA9 Transcription Factor Inhibitors: Design, Molecular Evaluation, and Cellular Consequences in a HOXA9-Dependant Leukemia Cell Model.
AID38040Drug concentration required to inhibit B16 cell growth by 50% after 72 hours of incubation2002Journal of medicinal chemistry, May-09, Volume: 45, Issue:10
Distribution of furamidine analogues in tumor cells: influence of the number of positive charges.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.97 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
netropsin
Netropsin: A basic polypeptide isolated from Streptomyces netropsis. It is cytotoxic and its strong, specific binding to A-T areas of DNA is useful to genetics research.		2.110
pentamidine
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.		1.9910aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
furamidine
furamidine: RN given refers to parent cpd; WR 199385 refers to di-HCl; pafuramidine is a prodrug of this		2.9640
biotin
vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.		2.0110biotins;
vitamin B7		coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite
db 244
[no description available]		1.9910
furimidazoline
furimidazoline: structure in first source		2.0110
oligonucleotides
[no description available]		2.0110
ConditionIndicatedRelationship StrengthStudiesTrials
P carinii Pneumonia
[description not available]		01.9910
Pneumonia, Pneumocystis
A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.		01.9910
Leucocythaemia
[description not available]		02.2110
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		02.2110